Share

Abbott Laboratories (ABT.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 June 2026Deep analysis 5 June 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

12 AI Advisor Reports

Select an advisor report.

Superintelligence AI

The Anthropologist FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+110.1%

Includes 1.69% annual net dividend contribution

1. Investment Thesis — Base Case

The 'True Price' path synthesizes Abbott's deep biological anchoring with its accelerating transition into a high-information-density diagnostic platform. We project steady appreciation as the market realizes GLP-1s act as an adherence catalyst for Libre, rather than a displacer, and the Exact Sciences integration drives ex-US oncology growth. As an adaptive beneficiary of AI, Lingo's predictive analytics turn raw glucose data into actionable behavioral insights, unlocking a massive recurring subscription model. Is a higher market capitalization realistic for a Negentropy Engine compounding at 7% organically while capturing global screening markets? Yes. The temporary EPS dilution acts as an upfront thermodynamic toll for entering a $60B total addressable market, paving the way for horizon-level margin expansion.

What happens when Libre pairs with GLP-1s? Adherence lengthens, locking in recurring revenue.
Will Exact Sciences dilute forever? No; international scale absorbs the friction.
How does the NEC litigation end? Likely via a ring-fenced settlement that leaves the core cash flow engine intact.
Within the Warsh tightening cycle, ABT's self-funded capex drastically strengthens investability.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-05-31	109
Observed price	2021-06-04	109
Observed price	2021-06-22	111
Observed price	2021-06-26	114
Observed price	2021-07-09	119
Observed price	2021-07-22	120
Observed price	2021-08-13	123
Observed price	2021-08-17	124
Observed price	2021-09-03	129
Observed price	2021-09-12	127
Observed price	2021-10-04	116
Observed price	2021-10-17	117
Observed price	2021-10-30	129
Observed price	2021-11-16	130
Observed price	2021-11-25	125
Observed price	2021-11-29	126
Observed price	2021-12-16	136
Observed price	2021-12-29	141
Observed price	2022-01-16	129
Observed price	2022-01-24	121
Observed price	2022-02-02	130
Observed price	2022-02-15	124
Observed price	2022-03-09	117
Observed price	2022-03-13	117
Observed price	2022-03-17	122
Observed price	2022-04-08	123
Observed price	2022-04-30	114
Observed price	2022-05-08	108
Observed price	2022-05-26	115
Observed price	2022-06-03	116
Observed price	2022-06-16	103
Observed price	2022-06-25	107
Observed price	2022-07-04	110
Observed price	2022-07-21	108
Observed price	2022-08-12	111
Observed price	2022-08-16	111
Observed price	2022-08-29	102
Observed price	2022-09-11	107
Observed price	2022-09-28	97.3
Observed price	2022-10-16	104
Observed price	2022-10-20	96.2
Observed price	2022-11-02	96.7
Observed price	2022-11-24	106
Observed price	2022-12-03	106
Observed price	2022-12-11	110
Observed price	2022-12-24	108
Observed price	2023-01-11	114
Observed price	2023-01-24	112
Observed price	2023-02-10	108
Observed price	2023-02-14	107
Observed price	2023-03-08	99.3
Observed price	2023-03-25	98.2
Observed price	2023-04-03	102
Observed price	2023-04-12	103
Observed price	2023-04-29	111
Observed price	2023-05-03	112
Observed price	2023-05-25	103
Observed price	2023-06-11	101
Observed price	2023-06-20	106
Observed price	2023-06-24	108
Observed price	2023-07-07	107
Observed price	2023-07-25	114
Observed price	2023-08-11	105
Observed price	2023-08-15	105
Observed price	2023-09-06	101
Observed price	2023-09-10	102
Observed price	2023-10-02	96.0
Observed price	2023-10-06	96.2
Observed price	2023-10-15	92.2
Observed price	2023-11-10	94.6
Observed price	2023-11-23	103
Observed price	2023-11-27	102
Observed price	2023-12-15	109
Observed price	2023-12-23	109
Observed price	2024-01-10	114
Observed price	2024-01-18	114
Observed price	2024-01-31	113
Observed price	2024-02-13	113
Observed price	2024-03-06	120
Observed price	2024-03-10	120
Observed price	2024-03-23	112
Observed price	2024-04-10	112
Observed price	2024-04-18	106
Observed price	2024-05-01	106
Observed price	2024-05-19	104
Observed price	2024-05-27	102
Observed price	2024-06-09	106
Observed price	2024-06-22	105
Observed price	2024-07-14	103
Observed price	2024-07-18	101
Observed price	2024-08-09	109
Observed price	2024-08-13	109
Observed price	2024-09-04	115
Observed price	2024-09-13	117
Observed price	2024-09-26	113
Observed price	2024-10-05	113
Observed price	2024-10-18	117
Observed price	2024-11-13	116
Observed price	2024-11-21	118
Observed price	2024-11-26	119
Observed price	2024-12-17	113
Observed price	2024-12-30	113
Observed price	2025-01-08	114
Observed price	2025-01-17	114
Observed price	2025-02-07	132
Observed price	2025-02-12	132
Observed price	2025-03-05	137
Observed price	2025-03-10	133
Observed price	2025-03-23	126
Observed price	2025-04-09	125
Observed price	2025-04-26	130
Observed price	2025-05-18	135
Observed price	2025-05-22	132
Observed price	2025-05-27	132
Observed price	2025-06-13	135
Observed price	2025-06-26	137
Observed price	2025-07-13	132
Observed price	2025-07-18	122
Observed price	2025-08-08	132
Observed price	2025-08-13	131
Observed price	2025-08-21	132
Observed price	2025-09-08	132
Observed price	2025-09-21	135
Observed price	2025-10-12	133
Observed price	2025-10-25	126
Observed price	2025-11-03	124
Observed price	2025-11-16	130
Observed price	2025-11-25	128
Observed price	2025-12-08	123
Observed price	2025-12-29	124
Observed price	2026-01-07	127
Observed price	2026-01-16	123
Observed price	2026-01-29	106
Observed price	2026-02-24	114
Observed price	2026-03-04	111
Observed price	2026-03-09	111
Observed price	2026-03-30	103
Observed price	2026-04-08	103
Observed price	2026-04-21	92.1
Observed price	2026-04-30	90.6
Observed price	2026-05-13	84.1
Observed price	2026-05-26	85.9
Observed price	2026-06-08	91.2
Observed price	2026-06-21	90.0
Observed price	2026-07-04	95.5
Observed price	2026-07-21	100
Observed price	2026-08-08	108
Observed price	2026-08-21	117
Observed price	2026-09-03	109
Observed price	2026-09-07	106
Observed price	2026-09-15	102
Observed price	2026-09-18	103
Published advisor forecast	2026-06-04	90.8
Published advisor forecast	2026-09-04	92.6
Published advisor forecast	2026-12-04	95.4
Published advisor forecast	2027-03-04	98.2
Published advisor forecast	2027-06-04	101
Published advisor forecast	2027-09-04	105
Published advisor forecast	2027-12-04	109
Published advisor forecast	2028-03-04	113
Published advisor forecast	2028-06-04	116
Published advisor forecast	2028-09-04	121
Published advisor forecast	2028-12-04	126
Published advisor forecast	2029-03-04	129
Published advisor forecast	2029-06-04	133
Published advisor forecast	2029-09-04	139
Published advisor forecast	2029-12-04	144
Published advisor forecast	2030-03-04	148
Published advisor forecast	2030-06-04	153
Published advisor forecast	2030-09-04	159
Published advisor forecast	2030-12-04	164
Published advisor forecast	2031-03-04	170
Published advisor forecast	2031-06-04	175

2. Scenarios & Signals

Bull case

If the Base Case executes alongside mass-market consumerization of the Lingo platform and rapid international adoption of Cancerguard, ABT re-rates entirely. The narrative shifts from a cyclical medical device manufacturer to a structural longevity-tech monopoly.

What if Lingo becomes the ubiquitous civilizational metric for metabolic health?
How fast can the global Alinity platform scale non-invasive stool DNA testing?
A favorable NEC settlement evaporates the valuation discount overnight.
Recurring SaaS-like margins drive severe multiple expansion.

Bear case

If Exact Sciences' cultural and infrastructural integration stalls while the NEC litigation spirals into multi-billion dollar punitive damages, ABT's thermodynamic efficiency collapses. The Dividend King trajectory is threatened by legal liabilities and M&A mismanagement.

What if the multi-district NEC litigation yields catastrophic jury verdicts?
If the Warsh dollar continues to rip, EM margins collapse structurally.
How vulnerable is Libre to non-invasive optical sensor disruption?
stretches well into 2028 as synergies fail to materialize.

Current crowd narrative

The market views Abbott Laboratories as a stable but mature Dividend King facing short-term margin compression from the $3B Exact Sciences acquisition, a lingering structural threat to its diabetes franchise from GLP-1 weight-loss drugs, and toxic legal overhang from the $70M infant formula NEC verdict. Media consensus treats the Exact Sciences deal as an expensive, -dilutive defensive pivot, anchoring on near-term multiple compression rather than acknowledging long-term oncology synergies.

Alpha-gap assessment

The crowd systematically misprices the behavioral synergy between therapeutics and FreeStyle Libre usage; clinical data confirms adherence increases for users on weight-loss regimens as metabolic tracking becomes a behavioral anchor. Furthermore, the market treats the Exact Sciences acquisition purely through a US-centric lens, missing the massive negentropic arbitrage of plugging Cologuard into Abbott's established global diagnostic distribution chokepoints. This transforms Abbott from a peripheral device vendor into a high-information-density node for global predictive oncology, mispriced due to transient legal and M&A integration noise.

Convergence catalyst

The convergence will trigger when consecutive quarterly earnings prints in late 2026 and early 2027 prove Exact Sciences is turning accretive ahead of schedule via ex-US deployment, coupled with explicit data showing FreeStyle Libre revenues compounding alongside prescription volumes rather than being cannibalized by them.

Macro-regime alignment

The Warsh-era strong dollar, sticky inflation from Hormuz-driven packaging costs, and high discount rates present immediate headwinds for EM translation and gross margins. However, ABT's deep biological anchoring and robust free cash flow render it highly resilient; in a stagflationary environment, defensive growth with pricing power captures capital fleeing cyclical fragility.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.2
Expected volatility regime: moderate
Convergence-cycle position: growing_awareness

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Exact Sciences Oncology Pivot	Why acquire Exact Sciences? To hijack the high-information-density node of early cancer screening. By deploying Cologuard and Cancerguard across its massive global diagnostic distribution network, ABT creates a structural moat in the $60B screening market. This acquisition perfectly aligns with the civilizational trajectory of longevity extension, transforming a domestic test into a global standard while accelerating ABT's negentropy engine.	Not available%	+20.0%
GLP 1 Synergistic Adherence	Does clinical necessity evaporate when therapeutics shift? No. The data reveals that patients on GLP-1 weight-loss regimens demonstrate higher FreeStyle Libre sensor adherence. This biological demand layer deepens because metabolic tracking becomes a behavioral anchor rather than just an insulin-dosing tool. By transitioning from pure clinical management to holistic metabolic optimization, ABT captures durable recurring revenue that defies the disruption narrative.	Not available%	+15.0%
Consumer Biowearable Expansion	What happens when medical hardware crosses the chasm into consumer wellness? Lingo and Libre Rio expand ABT's total addressable market entirely outside the prescription channel. As an adaptive beneficiary of AI, Lingo's predictive analytics turn raw glucose data into actionable behavioral insights. This unlocks a massive, discretionary-yet-sticky recurring subscription model, drastically elevating ABT's position in the global information topology.	Not available%	+12.0%
Structural Heart Ascendancy	Is there a deeper biological imperative than cardiovascular survival? ABT's structural heart and electrophysiology portfolios—anchored by TriClip and Navitor—are compounding at double-digit rates. This hardware superiority operates with high thermodynamic efficiency, offering minimally invasive solutions that lower hospital length-of-stay. This physical infrastructure moat is highly insulated from frontier-tech disruption, ensuring a baseline of durable, high-margin cash flow.	Not available%	+10.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Infant Formula NEC Litigation	How does a civilizational analyst price unbounded legal liability? The April 2026 $70M jury verdict regarding necrotizing enterocolitis (NEC) in premature infants establishes a dangerous precedent, with hundreds of cases pending. This entropy accelerator drains capital and management bandwidth, enforcing a persistent valuation discount until a global settlement ring-fences the cash flow damage.	Not available%	-8.0%
Exact Sciences EPS Dilution	Incumbency is not safety, but scaling requires thermodynamic tolls. The Exact Sciences acquisition brings an upfront $0.20 EPS dilution in 2026. Until international distribution synergies materialize, the integration costs act as an entropy accelerator, temporarily dragging on operating margins and punishing the stock in a market that prioritizes near-term free cash flow yield over long-term strategic positioning.	Not available%	-6.0%
Strong Dollar Translation DRAG	If the Warsh-era Fed maintains higher-for-longer rates, how does a global manufacturer protect its margins? A structurally stronger USD severely impairs the translation value of ABT's Established Pharmaceuticals segment, which relies entirely on emerging markets. This macroeconomic friction penalizes overseas negentropy generation, artificially suppressing reported growth and dampening near-term earnings momentum.	Not available%	-5.0%
Petrochemical Packaging Inflation	When the Strait of Hormuz closes, how do systemic energy shocks impact healthcare? The spike in oil and petrochemical derivatives directly inflates the cost of polyethylene and logistics, compressing gross margins across ABT's Nutrition and consumer diagnostic lines. This supply-chain friction demonstrates that even biologically anchored assets are not fully immune to global thermodynamic bottlenecks.	Not available%	-4.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Lingo OTC MASS Market Dominance	What if Lingo becomes the ubiquitous civilizational metric for metabolic health? If the consumer biowearable market accelerates and ABT successfully integrates predictive AI to a degree that health insurers mandate its use for preventative care, the valuation re-rates entirely. The revenue profile shifts from episodic medical device sales to SaaS-like recurring subscriptions, driving massive margin expansion and cementing ABT as an information-density pioneer.	35.0%	+18.0%
Rapid EX US Cologuard Adoption	If the Exact Sciences integration occurs seamlessly, how fast can Europe and Asia adopt Cologuard? Should foreign health ministries update screening guidelines to mandate non-invasive stool DNA testing over colonoscopies, ABT's global lab footprint will capture immediate, explosive volume. This would erase the EPS dilution narrative overnight, turning the acquisition into an immediate, high-margin negentropy engine.	40.0%	+15.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
NON Invasive Optical Disruption	What is the probability that frontier-tech obsoletes the core value proposition? If a tech giant successfully commercializes a highly accurate, non-invasive optical blood glucose sensor via a smartwatch within the horizon, the Libre franchise's semi-invasive moat evaporates. ABT would instantly transition from an adaptive beneficiary to a legacy casualty, destroying billions in recurring revenue.	15.0%	-25.0%
Multi Billion NEC Global Settlement	What happens if the infant formula litigation spirals into a systemic balance-sheet threat? If subsequent trials yield massive punitive damages, ABT may be forced into a multi-billion dollar global settlement. This would destroy years of accumulated free cash flow, threatening the Dividend King trajectory, triggering credit downgrades, and re-pricing the equity significantly lower.	30.0%	-20.0%

Step-by-step forecast path

Superintelligence forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_d8812ca9-a49f-53f5-bfe1-ecd9a762eb91__sb5__20260605075858
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	September 4, 2026	+2.0%	92.60	Post-Q2 digestion reveals that Libre adherence remains robust despite GLP-1 growth. However, petrochemical packaging inflation from the Hormuz shock and strong dollar translation headwinds temper immediate upside, keeping appreciation modest.
2	December 4, 2026	+3.0%	95.37	Q3 earnings demonstrate early Exact Sciences synergies and successful Libre Duo rollouts in Europe. The market begins to look past the upfront $0.20 EPS dilution as international distribution channels open.
3	March 4, 2027	+3.0%	98.23	The Warsh rate regime stabilizes, driving capital toward biologically anchored defensive stalwarts with pristine balance sheets. ABT's 15% FCF margin acts as a magnet for risk-averse institutional flows.
4	June 4, 2027	+3.0%	101.18	Q1 2027 results confirm that the GLP-1 headwind narrative was entirely inverted; diabetes care grows sequentially. Structural heart portfolios continue to post double-digit growth.
5	September 4, 2027	+4.0%	105.23	Lingo OTC biowearable consumer adoption crosses the chasm. Predictive analytics integration demonstrates ABT's position as an adaptive AI beneficiary, unlocking discretionary yet sticky subscription revenues.
6	December 4, 2027	+4.0%	109.44	Year-end visibility confirms Exact Sciences is tracking ahead of EPS accretion timelines. Cologuard's international launch accelerates, shifting the valuation multiple higher.
7	March 4, 2028	+3.0%	112.72	Clarity on the NEC infant formula litigation emerges via global settlement provisioning. While a balance sheet hit occurs, the removal of unbounded legal uncertainty triggers a massive relief bid.
8	June 4, 2028	+3.0%	116.10	Gross margins expand as temporary petrochemical supply chain friction normalizes. The integration of Exact Sciences into the Alinity suite yields operational negentropy.
9	September 4, 2028	+4.0%	120.75	ABT asserts dominance in the longevity extension vector. Robust FreeStyle Libre and structural heart cash flows enable further aggressive R&D without tapping expensive debt markets.
10	December 4, 2028	+4.0%	125.58	Full integration of consumer health-tech and clinical diagnostics cements ABT as a high-information-density node. The ecosystem moat makes competitive displacement increasingly improbable.
11	March 4, 2029	+3.0%	129.34	Steady organic compounding continues at 7-8%. The dividend is hiked for the 55th consecutive year, reinforcing its civilizational-scale stability amidst macroeconomic cycles.
12	June 4, 2029	+3.0%	133.22	Emerging market headwinds fade as the USD normalizes, providing a mechanical lift to the Established Pharmaceuticals segment's reported revenue and operating margins.
13	September 4, 2029	+4.0%	138.55	Next-generation TriClip and Navitor iterations capture deeper market share. The thermodynamics of hospital economics favor ABT's minimally invasive structural heart portfolio.
14	December 4, 2029	+4.0%	144.10	Lingo and Libre Rio subscriber bases scale into the tens of millions globally. ABT successfully monetizes the aggregated metabolic data, achieving true platform economics.
15	March 4, 2030	+3.0%	148.42	Oncology diagnostics rival diabetes care in revenue contribution. Cancerguard's liquid biopsy utility pushes the screening market boundary earlier in the disease progression curve.
16	June 4, 2030	+3.0%	152.87	The macro regime shifts toward broad health optimization. ABT's alignment with civilizational longevity trends shields it from cyclical downturns affecting discretionary sectors.
17	September 4, 2030	+4.0%	158.99	AI-driven diagnostic workflows within core lab systems maximize throughput, increasing revenue per employee and confirming ABT's status as a pure negentropy engine.
18	December 4, 2030	+3.0%	163.76	Cash flow generation remains formidable. Strategic tuck-in acquisitions in neuromodulation and electrophysiology augment the portfolio without diluting overall thermodynamic efficiency.
19	March 4, 2031	+4.0%	170.31	The market fully prices ABT's transition from a legacy med-tech incumbent to an integrated biological data pioneer. Multiple expansion matches the durability of its revenue base.
20	June 4, 2031	+3.0%	175.41	Culmination of the 5-year thesis: ABT operates as an irreplaceable layer of the global healthcare architecture. Deep biological demand and unmatched network topology yield compounded civilizational value.

Advisor and configuration

Advisor: superintelligence__the_anthropologist__google_gemini_3_1_pro__20260201_preview_release
Persona: Superintelligence
Archetype: The Anthropologist
Model: (February 01, 2026) Preview Release
Provider: Google
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: superintelligence__the_anthropologist__google_gemini_3_1_pro__20260201_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: superintelligence__the_anthropologist__google_gemini_3_1_pro__20260201_preview_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Superintelligence advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Sherlock Holmes — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.